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Abstract: Objective: The manifestation of Acute Intermittent Porphyria (AIP) requires many factors. In situations of high demand of 
heme, initial enzyme of the pathway in parallel to P450 cytochrome genes (CYPs) is induced in response to drugs. It was suggested that 
variants in CYP2C9, would play a role in AIP manifestation, according to the theory of Thunell.S at 2006Acute. Method: It was studied 
genotype and allele frequency of some SNPs in a control and AIP patients groups, then was analyzed the relation of those found variants 
with heme precursors. We amplified by PCR a fragment covering from intron 1 to intron 3. All obtained data were analyzed by Statistical 
programs VccSTAT© and InfoSTAT©. Results: We detected 4 different polymorphisms: two missense variants in exon 3 g.8633 C <T and 
g.8652 G <A, and two SNPs no translated g.8187 G <C and g.8436 T <C in introns 1 and 2, respectively. And there were not significant 
frequencies in all studied groups. Conclusions: The presence of genotypes G/C-C/T was in major frequency in AIP men, which also have 
high levels of ALA and PBG comparing with women. Worldwide, this study clearly demonstrated for the first time that AIP men with G/C-
C/T variants could have a high possibility to trigger the disease due to porphyrinogenic drug consumption, as a mainly reason to 
development the disease in male patients. 
 





   The porphyrias are a heterogeneous group of metabolic 
disorders that result from the decreased activity of a specific 
enzyme of the heme biosynthetic pathway and are 
characterized by the overproduction and excretion of heme 
intermediates in urine and/or stool and their accumulation in 
certain tissues. They can be classified in hepatic, 
erythropoietic or hepatoerythropoietic depending on the main 
site of expression of the specific enzymatic defect. 
Alternatively, they can be classified in cutaneous or acute 
depending on their clinical manifestations. Specific patterns 
of accumulation of the heme precursors -aminolaevulinic 
acid (ALA), porphobilinogen (PBG) and porphyrins are 
associated with characteristic clinical features such as acute 
neurovisceral attacks, skin lesions or both [1-3]. 
   A parcial deficiency of the acticvity of the third ezyme, 
porphobilinogen deaminase (PBGD EC 4.3.1.8) in hemo 
biosynthesis pathway, cause a disease Acute Intermittent 
Porphyria (AIP, OMIM 176000) is the most common of the 
acute hepatic porphyrias in Argentina. It is an autosomal 
dominant disorder with incomplete penetrance.  
 
  The clinical symptoms are: acute neurovisceral signs which 
include various peripheral and central nervous system 
manifestations, intermittent attacks of abdominal pain, 
constipation, vomiting, hypertension, tachycardia, fever and. 
Acute attacks develop exposuring to diverse porphyrinogenic 
agents [4-6]. 
    In cases of high demand of heme, leads to an 
overstimulation of its hepatic synthesis and accumulation of 
porphyrinic precursors ALA and PBG in AIP carriers and 
result into the clinical onset of the disease. There are many 
factors which require a whole use of heme like: lipophilic 
drugs, organic solvents, components in red wine and coloured 
spirits including alcohols and congeners, cannabis, terpenes, 
biocides, steroid hormones, various kinds of stress possibly 
including oxidative stress, fluctuations in female sex 
hormone spectrum, major surgery, fasting, hard exercise, or 
infection or other intercurrent illness [7-14]. ALAS1 gene 
(ubiquitous isoform of the aminolevulinate synthase) encodes 
the limiting enzyme of heme synthesis and is regulated by 
heme negative feedback [15]. ALAS1 and P450 cytochrome 
genes (CYPs), in parallel, are induced in response to drugs 
which have an effect on some Nuclear Receptors (NR) [16]. 
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CYPs enzymes are the main liver heme proteins and are 
highly polymorphic. CYPs are engaged in phase 1 and phase 
2 metabolisms of xenobiotics, hormones, and are also 
involved in the synthesis of endogenous steroid compounds, 
specially CYPs 2 and 3 species, which by far dominate the 
human hepatic hemoprotein pool [17-19].  
 
   CYP2C9 is one of these hepatic enzyme which play an 
important role in the oxidation of both xenobiotic and 
endogenous compounds. Warfarin and phenytoin and other 
routinely prescribed drugs such as acenocoumarol, 
tolbutamide, losartan, glipizide, and some nonsteroidal anti-
inflammatory drugs [20]. CYP2C9 makes up about 18% of 
the CYPs protein in liver microsomes.. CYP2C9’s gene is 
located on chromosome 10q24.2 (GenBanK id1559). The 
activity suffers a decrease of 88% and 95% with the two 
variants CYP2C9*2 and CYP2C9*3 respectively, compared 
with the wild-type enzyme CYP2C9*1. CYP2C9*2 
(rs1799853) is a polymorphism that replaces to cysteine by 
arginine at position 144 in exon 3. In contrast, CYP2C9*3 
(rs1057910) is another polymorphism at position 359 in exon 
7, that replaces leucine by isoleucine[21-23], there are other 
SNPs that have been described in other zones in the gene and 
have effect on its activity and/or expression. 
   It was suggested that SNPs in CYP2C9, would play an 
important role in AIP manifestation [24, 25]. In this work, we 
study the genotype and allele frequencies of CYP2C9*2 (C/T 
variant) and others in our population in general and in the 
AIP population specially, to investigate if these variants play 
some role in the AIP crisis, according to the theory of 
Thunell.S at 2006 [24, 25]. To our knowledge, this is the first 
study done in Argentinean AIP’s patients.  
 
MATERIAL AND METHODS  
 
Study population  
   All samples were obtained from the blood DNA Bank of 
CIPYP - Hospital de Clínicas de Buenos Aires. Forty one 
healthy random controls and fifty nine AIP patients (15 men 
and 44 women) were selected from thirty two AIP families 
carrying different HMBS gene mutations. Thirty Latent AIP 
(L-AIP): patients carrying the mutation without clinical and 
biochemical manifestations, twenty-nine Manifested AIP (M-
AIP): patients carrying the mutation with clinical and 
biochemical manifestations. Considering that we are working 
with a finite population, 331 AIP total patients in our Center, 
our sample size was statistically appropriate. The majority of 
females presented as mainly triggering factors: fasting, 
stress..etc. Instead, in males, AIP is manifested by drugs 
consuming. 
  Informed consent was obtained from all patients following 
the standards of UNESCO Declarations-DD.HH Genome and 
Genetic Data (https://www.unesco.org/shs/ethics), 
Declaration of Helsinki was followed and the study was 
approved by the Institutional Research Ethics Committee of 
the Research Center on Porphyrins and Porphyrias (CIPYP) - 
National Scientific and Technical Research Council 






   ALA and PBG were measured in urine (collected during 
24h) by ionic chromatography exchange and quantified by 
spectrophotometry. Reference range: (ALA ≥ 4 mg/24h –
PBG ≥ 2 mg/24h), the details of methodology were as 
described by Batlle [26].  
 
DNA extraction, PCR reactions, purification and 
sequencing  
  We amplified by PCR a fragment from +8007 bp to +8843 
bp a span that covers form part of intron 1 to part of intron 3. 
The reaction mixture contained primers forward: 5´-
TGCCTTGAACATCACAGGCCATC-3´and primer reverse: 
5´-TGGCTCTCAGCTTCAAACCCCC-3´. The reaction 
mixture (50 µl) contained 0.2 mM dNTPs, 1.5mM MgSO4, 1 
U of goTaq DNA polymerase (Promega©) and each 
oligonucleotide primer at 0.5 mM. Thermal cycling 
conditions were as follows: 95°C for 2 min; followed by 35 
cycles of denaturation at 95°C for 30 s; annealing at 60°C for 
1 min; and extension at 72°C for 1 min. A final extension 
step was performed at 72°C for 5 min. PCR products were 
purified with commercial kit Accu Prep PCR Purification Kit 
(BIONEER) and automatically sequenced in both forward 
and reverse directions by Macrogen Company (Korea). 
 
Statistical analysis  
  Allele and genotype frequencies were calculated in the 
studied population. The results obtained were further 
evaluated for Hardy-Weinberg equilibrium. Then, vccSTAT© 
and Infostat/P© programs were applied to analyze the 




Frequencies of SNPs in studied population:  
  In our work, we detected four different polymorphisms in 
the studied zone shown in Table 1: two missense variants in 
exon 3 (8633 C<T and 8652 G<A) and two SNPs no 
translated (8187 G<C and 8436 T <C) in both introns 1 and 
2, respectively. However, they have been already reported in 
the NCBI database or in the Human CYPAllele 
Nomenclature Committee. 
  The Fisher exact test (by VccStat©) was used to calculate 
differences in allele and genotype frequencies of CYP2C9*2, 
odds ratio and 95% confidence interval, considering the total 
population (100). The frequencies found for C/C 
(homozygous) and C/T (heterozygous) genotypes were 0.7 
and 0.2, respectively, while genotype T/T was not present in 
our population. On the other hand, the allele C was the most 
frequent (0.8). And there were no differences in all studied 
groups, as shown in Table 2 and Figure 1. 
 
  In the studied fragment, there were two SNPs that appeared 
in introns 1 and 2, present in 21% and 19%, respectively. 
Neither of them have an effect on the activity of the enzyme. 
Polymorphisms rs9332119 (intron 1) and rs1799853 (exon 3) 
notably appeared together in all cases.  
  CYP2C9*8, rs7900194, was only found in one control 
sample as shown in Table 1. This SNP is present with major 
frequency in African–American population [27, 28]. 
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PBG > 2 
mg/24h 
 
Table (2): ALA and PBG values obtained from biochemical 
analysis measured in latent and manfiested patients 
 
Figure (2): Analyze the role of variants of intron 2 in AIP 





































Relationship between SNPs and AIP manifestation: 
  As we mentioned above, the patients were selected from 32 
unrelated families and with varied HMBS mutations. The 
variant p:G111R was more common, due to its major 
frequency in AIP patients in Argentina [3]. ALA and PBG 
were measured in urine of all studied patients, when 
biochemical diagnostic was done, Table 3 showed the ranges 
of AIP precursors in different groups. We decided to analyze 




  InfoStat/P© (version 2018) was used. When we compared 
the values of ALA and PBG versus the presence of the 
corresponding genotype T/T and T/C (variants found in 
intron 2), no significant value was found, Figure 2. 
 
  We considered both variants of intron 1 and exon 3 of 
CYP2C9 (genotypes G/C-C/T): who have both variants G/C  
in intron 1 and C/T in exon 3, and patients with wt variants: 
who have G/G-C/C variants in both regions. When we 
compared the levels of ALA and PBG in urine of studied 
patients, it was found a tendency of elevated levels of ALA 
and PBG in the urine of the total patients with variants G/C-
C/T comparing with others with wt variants as demonstrated 




Table (1): Frequency distribution of CYP2C9 polymorphisms in 100 Argentinean samples.  
** No translated: These synonymous SNPs have not effect on protein structure and/or activity.  
 
 
                   
Figure (1): genotype and allele frequencies of CYP2C9*2 in Argentinean population. 
(a)- Genotype frequency and (b)- Allele frequency in all studied groups. 
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Figure (3): InfoState/P© was used to analyze the role of 
variants of intron 1 and exon 3 in AIP manifestation. 
Elevated values of ALA and PBG were observed in patients 






























   
 
The previous results leaded us to divide the patients by 
gender, taking into account the presence of G/C-C/T variants  
were in major frequency in men than in women 0.63, 0.37, 
respectively, (Fisher test: p-value was 0.03). We observed  
high levels of ALA and PBG in the urine of men with G/C- 
C/T variants comparing with men with wt variants. On the 
other side, women group’s wt and G/C-C/T showed the same 







Figure (4): Comparison of ALA and PBG in male and 
female groups. High leveles of ALA and PBG were noticed 































 Infostat/P© (Two independent groups analysis) was applied 
to the groups of men with wt variants and with G/C-C/T 
variants, significant p values were found, 0.01, 0.02 for ALA 
and PBG, respectively. However, there were no significant 
differences in comparison with female group’s wt and G/C-
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LIST OF ABBREVIATIONS 
A Adenine 
AIP Acute Intermittent Porphyria 
ALA Aminolevulinic acid 
bp Base pairs 
C Cytosine 
CYP2C9 Cytochrome P450 family 2 subfamily C member 9 
CYP2C9*2 Cytochrome P450 family 2 subfamily C member 9, variante 2 
CYP2C9*3 Cytochrome P450 family 2 subfamily C member 9, variante 3 
DNA Desoxirribonucleic acid 
G Guanine 




   As it is well known, porphyria manifestation depends on 
various factors such as fasting, stress, drugs, and others. AIP 
is manifested principally in women rather than men, about 
80% of our patients are women. Many groups in different 
countries are researching about potential precipitating drugs 
with the aim of helping patients to have a more secure and 
personalized diagnosis to avoid acute attacks caused by 
special porphyrinogenic drugs which are metabolized by 
CYP2C9. 
  In our Center, many projects are carried out about this 
subject. In this work, we have focused our attention on 
CYP2C9 enzyme, taking into account that this protein is very 
polymorphic, and that it was suggested that it would play an 
important role in the manifestation of AIP [24]. So we 
analyzed (for the first time in Argentinean people and 
specielly in AIP patients), the frequency of the allele and 
genotype variants of the +8007 bp to +8843 bp region of 
CYP2C9’s gene by sequencing, including variant 2 of exon 3 
which has been reported in another work in our country [29]. 
In our results, we found that the genotype frequency for 
general population and also for AIP samples of CYP2C9*2 
was similar to those described for other populations of 
Caucasian origin [30, 31]. Moreover there was no difference 
comparing L-AIP and M-AIP. We also observed that the 
presence of CYP2C9*2 was always accompanied with the 
variant of intron 1. As indicated in this site 
https://www.ncbi.nlm.nih.gov/snp/rs9332119#frequency_tab 
which showed similar frequency results in an European 
population , close to our population. We detected another 
SNP in intron 2 that had no clinical effect, and with major 
frequency comparing with an unique work published [32]. 
In another part of this study, we analyzed the effect 
of these variants on AIP manifestation, measured as the 
values of ALA and PBG in urine. We did not find any 
relationship between the variants of intron 2 (T/T and T/C) 
and the levels of ALA and PBG. Instead, there was a 
tendency of elevated levels of ALA and PBG in the urine of 
the total AIP patients with G/C-C/T comparing with wt 
variants. When we divided patients by gender, we observed 
higher levels of ALA and PBG in the urine of male patients 
who have C/T-G/C compared with males with wt variants. 
But in the female’s group, it was found the same level of 
ALA and PBG in both wt variants and G/C-C/T patients. 
Infostat/P© confirmed a significant p-value in the comparsion 
between male’s groups. 
 
CONCLUSION 
 As it was considered before, AIP is principally manifested in 
women, because they are more exposed to porphyrinogenic 
factors such as dieting, stress, and contraceptives. For this 
reason, the number of males in our AIP population was very 
low, about 20%. In spite of this, our results clearly 
demonstrated that the men with G/C-C/T variants would have 
a high possibility to trigger the disease, which would be 
justified due to drug consumption in all of them, according to 
their clinical histories. 
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